Merus NV
(FRA:2GH)
€
48.4
-0.4 (-0.82%)
Market Cap: 3.34 Bil
Enterprise Value: 3.04 Bil
PE Ratio: 0
PB Ratio: 8.88
GF Score: 57/100 Merus NV at Jefferies Healthcare Conference Transcript
Jun 10, 2022 / 04:45PM GMT
Release Date Price:
€13
Maury Raycroft
Jefferies, LLC - Analyst
Hi everyone, my name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies, and I'm happy to introduce our guest today, Bill Lundberg, the CEO of Merus. Thanks so much for joining us today, Bill.
Bill Lundberg
Merus N.V. - President, CEO & Principal Financial Officer, Executive Director
Thanks, Maury. Appreciate your support, appreciate the support from the entire team.
Questions & Answers
Maury Raycroft
Jefferies, LLC - Analyst
And we're going to do a fireside chat today. So maybe to start off, for those who are new to the story, if you can give a one-minute intro highlighting your main products and key catalyst [act].
Bill Lundberg
Merus N.V. - President, CEO & Principal Financial Officer, Executive Director
Merus is a Dutch company, originally focused on making bispecific and multi-specific antibodies for cancer therapy. Our technology is based on a common light chain platform, and that gives
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot